ResearchMoz

Browse All Vaccine Market Research Reports

List of reports from Vaccine

Displaying 1 to 30 (of 162 records)
Competitor Analysis: Cancer Vaccines
Mar 2014   |   By - La Merie Publishing
The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail...
$1112
In-depth Research on China Animal Vaccine Industry, 2014
Feb 2014   |   By - Huidian Research
At present, there are 88 animal vaccine manufacturers in China, with 338 production lines. But most of enterprises are small in scale, vaccine production inspection is not standard and product structures are not reasonable. Market shares are occupied by a minority of enterprises. According to the statistics by China Veterinary Drug Association (CVDA), the production capacity of live...
$2200
Vaccine Development Strategies - Refocusing Efforts to Address New Challenges
Feb 2014   |   By - CBR Pharma Insights
Vaccines are one of the most important healthcare advances and have saved millions of lives through immunizing against some of the most deadly diseases. With protection against a number of key viral and bacterial diseases now effectively generated, vaccine R&D is turning to areas of unmet need. Preventative vaccination in adults and against pathogens that affect the developing world is...
$3900
Global and China Swine Vaccine Industry 2014 Market Research Report
Feb 2014   |   By - QYResearch
The report firstly introduced Swine Vaccine basic information included Swine Vaccine definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Swine Vaccine industry policy and plan, Swine Vaccine product specification, manufacturing process,...
$2200
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease...
$9995
Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced...
$3495
Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced...
$3495
Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced...
$3495
Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced...
$3495
Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced...
$3495
Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced...
$3495
Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced...
$3495
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year...
$4995
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year...
$6995
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year...
$4995
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year...
$4995
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from...
$3495
Bimmugen (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Bimmugen (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from...
$3495
Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in...
$3495
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Jan 2014   |   By - GlobalData
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from...
$3495
Global and China H1N1 Vaccines Industry 2014 Market Research Report
Jan 2014   |   By - QYResearch
The report firstly introduced H1N1 Vaccines basic information included H1N1 Vaccines definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, H1N1 Vaccines industry policy and plan, H1N1 Vaccines product specification, manufacturing process,...
$2200
China Influenza Vaccine Industry 2014 Deep Research Report
Jan 2014   |   By - QYResearch
Firstly the report describes the background knowledge of Influenza Vaccine, including Concepts Classification Manufacturing process technical parameters and equipments List etc; then statistics International and China 16 Manufacturers Influenza Vaccine product 2009-2017 Capacity production cost price production value profit margins and other relevant data, statistics these enterprises...
$2200
Vaccine Partnering Terms and Agreements
Jan 2014   |   By - Current Partnering
The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in vaccine and adjuvant partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by...
$2995
Global and China Animal vaccine Industry 2013 Market Research Report
Dec 2013   |   By - QYResearch
The report firstly introduced Animal vaccine basic information included Animal vaccine definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Animal vaccine industry policy and plan, Animal vaccine product specification, manufacturing process,...
$2200
Infectious Vaccines Partnering Terms and Agreements
Dec 2013   |   By - Current Partnering
The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative...
$1995
Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis
Nov 2013   |   By - Renub Research
World Adult Vaccines Market – Market Overview   For much of the 20th century, vaccines were a pharmaceutical success story largely associated with children. Aggressive immunization programs eradicated Polio and Smallpox among developed nations and nearly eliminated Mumps, Pertussis, Measles, and other diseases. While Pediatric Vaccines are an important market, it is...
$1990
Cancer Vaccine Partnering Terms and Agreements
Nov 2013   |   By - Current Partnering
The Cancer Vaccine Partnering Agreements Terms and Agreements report provides comprehensive understanding and unprecedented access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements...
$1995
PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
Oct 2013   |   By - GlobalData
GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the...
$4995
PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
Oct 2013   |   By - GlobalData
GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines France Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons...
$4995
PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
Oct 2013   |   By - GlobalData
GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines Germany Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons...
$4995
 
Displaying 1 to 30 (of 162 records)

Popular Publishers

Transparency Market Research
ICD Research
Technavio
 
GBI Research
Winter Green Research
GlobalData

Popular Categories

 

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com

Upcoming Reports